Drug Profile
Verbrinacogene setparvovec - Freeline Therapeutics
Alternative Names: Adeno-associated viral vector; FLT-180aLatest Information Update: 23 Feb 2024
Price :
$50
*
At a glance
- Originator University College London
- Developer Freeline Therapeutics
- Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Gene therapies
- Mechanism of Action Factor IX replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Suspended Haemophilia B
Most Recent Events
- 20 Feb 2024 Freeline Therapeutics has been acquired by Syncona
- 20 Jul 2023 Freeline Therapeutics terminates a a phase I/II trial in Hemophilia B in USA and Austria (Parenteral, Infusion) due to pause in development of verbrinacogene setparvovec due to business priorities (NCT05164471) (EudraCT2021-001079-18)
- 24 May 2023 Freeline Therapeutics terminates a phase I/II trial in Haemophilia B in United Kingdom (Parenteral) due to its decision to pause development of the candidate for business priorities (NCT03641703)